CSL Behring is committed to helping people with Alpha-1 Antitrypsin Deficiency live full, healthy lives.

Alpha-1 Antitrypsin Deficiency is commonly called Alpha-1, AAT deficiency or genetic COPD. It is a hereditary disorder that may increase a person’s chances of developing lung disease such as chronic obstructive pulmonary disease (COPD) or emphysema.

The disorder is caused by a lack of the protein alpha-1 antitrypsin. This protein is made in the liver and protects the lungs from damage caused by infection and inhaled irritants such as smoke.¹

People with Alpha-1 have very low levels of alpha-1 antitrypsin, meaning their lungs don't have the same protection as people without the disorder. This leaves them at risk for life-threatening lung and/or liver diseases. ^3,4 The most serious liver diseases are cirrhosis and liver cancer.¹

Augmentation Therapy
Alpha-1 proteinase inhibitors treat this chronic disorder by replacing the missing alpha-1 antitrypsin protein.

• Zemaira®, CSL Behring’s Alpha-1 proteinase inhibitor, is the first Alpha-1 augmentation therapy approved by the US Food and Drug Administration as highly purified. In the US, Zemaira is indicated for chronic augmentation and maintenance therapy in adults with alpha-1 deficiency and clinical evidence of emphysema.

Early diagnosis and treatment are crucial to help those with Alpha-1 have the fullest life possible.

Diagnosis of Alpha-1 Antitrypsin Deficiency
Alpha-1 is often misdiagnosed as COPD, asthma or emphysema because the symptoms are similar: shortness of breath, chronic cough, difficulty breathing, and wheezing.¹ On average, people with Alpha-1 will see 3 doctors over 7 years before they are accurately diagnosed.² During that time, lung damage progresses.

Prevalence of Alpha-1 Antitrypsin Deficiency
Alpha-1 Antitrypsin Deficiency is one of the most common serious hereditary disorders.⁴

• Worldwide, 117 million people may have Alpha-1 Antitrypsin Deficiency-associated phenotypes ^4,5
• 3.4 million people are at risk of expressing severe Alpha-1^4,5
• Of the 100,000 people in the US estimated to have Alpha-1 Antitrypsin Deficiency,^3,4,6 approximately 95% don’t even know they have it^4,6
• About 3% of all people with COPD may have undetected Alpha-1¹

Testing for Alpha-1 Antitrypsin Deficiency
Alpha-1 is a laboratory diagnosis, not a clinical diagnosis. Therefore it can only be definitively diagnosed by a simple blood test. ⁷

Ask your healthcare professional whether you should be tested for Alpha-1 or visit www.Alpha1Answers.com for additional information about the condition.